Pro Medicus announces $16m US contract renewal

The Pro Medicus Ltd (ASX: PME) share price is in focus today after the company announced a five-year, $16 million contract renewal with The Ohio State University Wexner Medical Center. The deal adds new capabilities to an existing partnership and lifts the minimum commitments.

What did Pro Medicus report?

• Signed a five-year, A$16 million contract renewal with The Ohio State University Wexner Medical Center (OSUWMC)
• The contract now includes Visage 7 Workflow and Visage 7 Cardiology Imaging
• The agreement follows a transaction-based model with increased minimums and higher fees per transaction
• Total renewals for the financial year have reached A$141 million
• The agreement further strengthens Pro Medicus’ North American presence

What else do investors need to know?

Pro Medicus’ renewal with OSUWMC not only extends the existing relationship, but adds new product modules to the client’s platform, allowing the medical centre to phase out older systems. OSUWMC is a large, multi-disciplinary academic hospital, supporting over 1,400 beds and employing around 22,000 staff.

This renewal continues Pro Medicus’ trend of securing long-term, high-value contracts in the US healthcare sector, reinforcing its reputation for client retention and ongoing product innovation.

What did Pro Medicus management say?

Chief Executive Officer Dr Sam Hupert said:

Renewing this contract, to now include the additions of Visage 7 Workflow and Visage 7 Cardiology Imaging, confirms our belief that we have extensive native capabilities that Visage customers appreciate as they seek to retire legacy solutions and continue to scale their Visage 7 Enterprise Imaging Platform.

What’s next for Pro Medicus?

Ongoing renewals like this underpin Pro Medicus’ strategy to expand its cloud-based imaging footprint across large health networks. Management believes these multi-year deals provide sustainable revenue and highlight the demand for advanced imaging solutions.

The company looks set to continue investing in product enhancements, targeting further growth opportunities in North America and abroad as healthcare systems shift to enterprise-level, scalable platforms.

Pro Medicus share price snapshot

Over the last 12 months, the Pro Medicus shares have declined 44%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 3% over the same period.

View Original Announcement

The post Pro Medicus announces $16m US contract renewal appeared first on The Motley Fool Australia.

More reading

• Treasury Wine Estates kicks off 2026 Investor Day with a renewed transformation plan
• 5 things to watch on the ASX 200 on Thursday
• How much higher could Pro Medicus shares go? 2 brokers weigh in
• Here are the top 10 ASX 200 shares today
• Why the ASX 200 is rallying despite a weaker growth warning

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.